Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY

The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore

Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25

Aurobindo Pharma reports strong Q3 FY26 performance, boosted by Europe & ARV growth

Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million

Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth

Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum

Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26

The revenues this quarter are in line with the outlook we envisaged for the year